The dynamics of the cutaneous melanoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, and incremental healthcare spending across the world. In addition, in coming years due to the introduction of new therapies, the cutaneous melanoma market is predicted to grow by 2032.
LAS VEGAS, July 24, 2023 /PRNewswire/ -- DelveInsight's Cutaneous Melanoma Market Insights report includes a comprehensive understanding of current treatment practices including the major advancements in immunomodulatory and targeted therapies, cutaneous melanoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Cutaneous Melanoma Market Report
- As per DelveInsight analysis, the cutaneous melanoma market is expected to grow positively at a significant CAGR during the study period (2019–2032).
- As per Cancer Research UK, melanoma is the fifth most common cancer in the UK. There are around 16,200 new melanoma skin cancer cases in the UK every year. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035.
- Leading cutaneous melanoma companies such as IO Biotech, Merck Sharp & Dohme, Eisai, Regeneron Pharmaceuticals, BMS, Iovance Biotherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank Pharmaceuticals, Genentech, Inc., AstraZeneca, Incuron, Seagen Inc., Alkermes, OnKure, Inc., Syntrix Biosystems, Inc., Anaveon AG, IDEAYA Biosciences, MacroGenics, Novartis, Eli Lilly and Company, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, and others are developing novel cutaneous melanoma drugs that can be available in the cutaneous melanoma market in the coming years.
- Some key therapies for cutaneous melanoma treatment include IO102-IO103, LENVIMA (lenvatinib), Vidutolimod (CMP-001), Lifileucel (LN-144), BO-112 with Pembrolizumab, LNS8801, SB11285, Atezolizumab, Olaparib, FACT Complex-targeting Curaxin CBL0137, SGN-BB228, Nemvaleukin Alfa Subcutaneous, OKI-179 + binimetinib, SX-682, ANV419, IDE196, Lorigerlimab, KFA115, LY3300054, T-Vec, CMP-001, Pudexacianinium chloride, and others.
Discover which therapies are expected to grab the major cutaneous melanoma market share @ Cutaneous Melanoma Market Report
Cutaneous Melanoma Overview
Cutaneous melanoma is a type of skin cancer that develops in the melanocytes, the cells responsible for producing melanin, the pigment that gives color to the skin. It is the most aggressive form of skin cancer and can be life-threatening if not detected and treated early. Several factors can contribute to the development of cutaneous melanoma. One of the primary causes is excessive exposure to ultraviolet (UV) radiation from the sun or artificial tanning beds.
The symptoms of cutaneous melanoma can vary, but the most common sign is the appearance of a new mole or a change in an existing mole. It is important to be vigilant about any changes in the size, shape, color, or texture of moles, as well as the development of bleeding, itching, or ulceration. Other warning signs include asymmetrical moles, irregular borders, and moles that are larger than 6 millimeters in diameter. Diagnosing cutaneous melanoma involves a thorough examination of the skin and any suspicious moles. Dermatologists may use the ABCDE rule to assess moles: asymmetry, irregular borders, uneven color, diameter larger than 6 millimeters, and evolution or change over time.
Cutaneous Melanoma Epidemiology Segmentation
The cutaneous melanoma epidemiology section provides insights into the historical and current cutaneous melanoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and patient prevalent forecasts and models by exploring numerous studies and views of key opinion leaders.
The cutaneous melanoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Incident cases of Melanoma
- Incident Cases of Cutaneous Melanoma
- Stage-specific Incident Cases of Cutaneous melanoma
- Mutation-specific Incident Cases of Cutaneous Melanoma
- Age-specific Incident Cases of Cutaneous Melanoma
- Total Treated Cases of Cutaneous Melanoma
Cutaneous Melanoma Treatment Market
The treatment approach for cutaneous melanoma depends on various factors such as the stage of cancer, the size, and depth of the tumor, and whether it has spread to nearby lymph nodes or other organs. Surgical excision is often the primary cutaneous melanoma treatment method, involving the removal of the tumor along with a margin of healthy tissue. In some cases, a sentinel lymph node biopsy may be performed to determine if the cancer has spread. Additional cutaneous melanoma treatments may include immunotherapy, targeted therapy, radiation therapy, and chemotherapy, depending on the specific characteristics of the tumor and the individual patient. The choice of cutaneous melanoma treatment is determined by a multidisciplinary team of healthcare professionals, taking into consideration the patient's overall health and preferences. With advancements in medical research and technology, there is a growing focus on personalized treatment strategies to improve outcomes and enhance the quality of life for individuals affected by cutaneous melanoma.
In recent years, significant progress has been made in the treatment of cutaneous melanoma, offering new options and improved outcomes for patients. Immunotherapy, such as immune checkpoint inhibitors, has revolutionized the management of advanced melanoma. These medications work by stimulating the body's immune system to recognize and attack cancer cells. Targeted therapy, on the other hand, focuses on specific genetic mutations or alterations within the tumor cells, blocking their growth signals. These targeted therapies have shown promising results in patients with specific mutations like BRAF or NRAS.
To know more about cutaneous melanoma treatment, visit @ Cutaneous Melanoma Treatment Drugs
Key Cutaneous Melanoma Therapies and Companies
- IO102-IO103: IO Biotech
- LENVIMA (lenvatinib): Merck Sharp & Dohme/Eisai
- Vidutolimod (CMP-001): Regeneron Pharmaceuticals/BMS
- Lifileucel (LN-144): Iovance Biotherapeutics
- BO-112 with Pembrolizumab: Highlight Therapeutics
- LNS8801: Linnaeus Therapeutics
- SB11285: Spring Bank Pharmaceuticals
- Atezolizumab: Genentech, Inc.
- Olaparib: AstraZeneca
- FACT Complex-targeting Curaxin CBL0137: Incuron
- SGN-BB228: Seagen Inc.
- Nemvaleukin Alfa Subcutaneous: Alkermes
- OKI-179 + binimetinib: OnKure, Inc.
- SX-682: Syntrix Biosystems, Inc.
- ANV419: Anaveon AG
- IDE196: IDEAYA Biosciences
- Lorigerlimab: MacroGenics
- KFA115: Novartis
- LY3300054: Eli Lilly and Company
- T-Vec: Amgen
- CMP-001: Checkmate Pharmaceuticals
- Pudexacianinium chloride: Astellas Pharma Inc
Learn more about the FDA-approved drugs for cutaneous melanoma @ Drugs for Cutaneous Melanoma Treatment
Cutaneous Melanoma Market Dynamics
The cutaneous melanoma market is experiencing dynamic shifts driven by various factors. The rising incidence of melanoma, fueled by increasing exposure to risk factors such as ultraviolet radiation and genetic predisposition, has contributed to the cutaneous melanoma market's growth. Additionally, advancements in diagnostic techniques, including genetic testing and imaging technologies, have improved early detection and diagnosis, leading to better patient outcomes.
Moreover, the introduction of targeted therapies and immunotherapies has revolutionized the treatment landscape, providing more effective and personalized options for patients. Furthermore, ongoing research and development efforts are focused on exploring novel therapeutic approaches, including combination therapies and innovative treatment modalities.
However, several factors are impeding the growth of the cutaneous melanoma market. Challenges such as high treatment costs, limited access to healthcare, and regulatory complexities pose obstacles to cutaneous melanoma market growth. Moreover, the cutaneous melanoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Cutaneous Melanoma Companies | IO Biotech, Merck Sharp & Dohme, Eisai, Regeneron Pharmaceuticals, BMS, Iovance Biotherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank Pharmaceuticals, Genentech, Inc., AstraZeneca, Incuron, Seagen Inc., Alkermes, OnKure, Inc., Syntrix Biosystems, Inc., Anaveon AG, IDEAYA Biosciences, MacroGenics, Novartis, Eli Lilly and Company, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, and others |
Key Cutaneous Melanoma Therapies | IO102-IO103, LENVIMA (lenvatinib), Vidutolimod (CMP-001), Lifileucel (LN-144), BO-112 with Pembrolizumab, LNS8801, SB11285, Atezolizumab, Olaparib, FACT Complex-targeting Curaxin CBL0137, SGN-BB228, Nemvaleukin Alfa Subcutaneous, OKI-179 + binimetinib, SX-682, ANV419, IDE196, Lorigerlimab, KFA115, LY3300054, T-Vec, CMP-001, Pudexacianinium chloride, and others |
Scope of the Cutaneous Melanoma Market Report
- Cutaneous Melanoma Therapeutic Assessment: Cutaneous Melanoma current marketed and emerging therapies
- Cutaneous Melanoma Market Dynamics: Conjoint Analysis of Emerging Cutaneous Melanoma Drugs
- Cutaneous Melanoma Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's Views, Analyst's Views, Cutaneous Melanoma Market Access and Reimbursement
Discover more about cutaneous melanoma drugs in development @ Cutaneous Melanoma Clinical Trials
Table of Contents
1. | Cutaneous Melanoma Market Key Insights |
2. | Cutaneous Melanoma Market Report Introduction |
3. | Cutaneous Melanoma Market Overview at a Glance |
4. | Cutaneous Melanoma Market Executive Summary |
5. | Disease Background and Overview |
6. | Cutaneous Melanoma Treatment and Management |
7. | Cutaneous Melanoma Epidemiology and Patient Population |
8. | Patient Journey |
9. | Cutaneous Melanoma Marketed Drugs |
10. | Cutaneous Melanoma Emerging Drugs |
11. | Seven Major Cutaneous Melanoma Market Analysis |
12. | Cutaneous Melanoma Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Melanoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key melanoma companies, including BioMed Valley Discoveries, Inc, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, Galectin Therapeutics Inc., Eucure (Beijing) Biopharma Co., Ltd, Mologen AG, Ultimovacs ASA, Seagen Inc., MedImmune LLC, OnKure, Inc., among others.
Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies including Neon Therapeutics, BioNTech, Bristol-Myers Squibb, among others.
Refractory Metastatic Melanoma Pipeline
Refractory Metastatic Melanoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key refractory metastatic melanoma companies, including Idera Pharmaceuticals, BioNTech, Bristol-Myers Squibb, among others.
Refractory Metastatic Melanoma Market
Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory metastatic melanoma companies including Idera Pharmaceuticals, BioNTech, Bristol-Myers Squibb, among others.
For more insights into the Cutaneous Melanoma market, visit: Healthcare Blogs
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Stay ahead in business and understand the best-in-class strategies and latest trends shaping the healthcare domain. Get in touch with our experts @ Healthcare Competitive Intelligence Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:
Voltar noticias em Inglês